SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2019 / Cilt: 5 - Sayı: 2

Mesenchymal Stem Cell Production for Clinical Usage

Klinik Kullanım İçin Mezenkimal Kök Hücrelerin Hazırlanması

Zeynep Burçin GÖNEN
Nur Seda ŞAHİN
Pages
169–175
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to explain the characteristics of MSCs, the special production methods for their use in clinical practice, and their effects on various cells

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Mesenchymal stem cells MSC are multipotent cells that can differentiate into specialized cells such as osteoblasts, chondrocytes and adipocytes, and have the ability for self-renewal.
📊
Key Findings & Data:However, special production conditions are required for clinical usage.
💡
Conclusion & Impact:The aim of this review is to explain the characteristics of MSCs, the special production methods for their use in clinical practice, and their effects on various cells
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Mezenkimal kök hücre · Translasyonel tıp · GMP

Abstract

Mesenchymal stem cells MSC are multipotent cells that can differentiate into specialized cells such as osteoblasts, chondrocytes and adipocytes, and have the ability for self-renewal. However, special production conditions are required for clinical usage. GMP Good Manufacturing Practice Laboratory conditions may provide a high quality control system in translational medicine from basic stem cell research to clinical trials. The content and concentration of the enzyme, digestion period, the speed of the centrifuge and filter size may be among the variables that affect the characteristics of MSCs. The production methods, application and dose of MSCs for certain therapies should therefore be standardized according to the best clinical treatment available for the patient. The aim of this review is to explain the characteristics of MSCs, the special production methods for their use in clinical practice, and their effects on various cells

Özet

Mezenkimal kök hücreler MKH kendini yenileme potansiyeli olan, osteoblast, kondrosit ve adiposit gibi özelleşmiş hücrelere farklılaşabilme yeteneğine sahip, erişkin, multipotent hücrelerdir. Klinikte kullanılmaları için özel üretim koşulları gerekmektedir. GMP Good Manufacturing Practice- İyi Üretim Uygulamaları şartlarında hücre üretimi, temel kök hücre bilimlerinden klinik araştırmalara ve uygulamalara translasyon için yüksek bir kalite güvence sistemi sağlar. Üretim protokolünde kullanılan enzim içeriği ve konsantrasyonu, parçalanma süresi, santrifüj hız farklılıkları, filtre boyutu gibi değişkenler, MKH eldesindeki farklılıkları oluşturur. Uygun üretim, doz ve uygulama yolu standardize edilerek hastada en başarılı tedavi sonucuna ulaşılır. Derlemede, MKH' lerin özelliklerini ve klinikte kullanımlarına özgü olarak nasıl hazırlandıklarını ve hazırlanma esnasındaki değişkenlerin hücre üzerine etkilerini açıklanması amaçlanmıştır

🔖

Cite This Article

GÖNEN, Z. B., ŞAHİN, N. S. (2022). Mesenchymal Stem Cell Production for Clinical Usage. Akdeniz Tıp Dergisi, Cilt: 5 - Sayı: 2, 169–175. https://ajindex.com/articles/434384

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-17
  2. Pendleton C, Li Q, Chesler DA, Yuan K, GuerreroCazares H, Quinones-Hinojosa A. Mesenchymal stem cells derived from adipose tissue vs bone marrow: In vitro comparison of their tropism towards gliomas. PLoS One 2013;8:581-98
  3. Thirumala S, Goebel WS, Woods EJ. Clinical grade adult stem cell banking. Organogenesis 2009;5:143-54
  4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7
  5. Li H, Ghazanfari R, Zacharaki D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann NY Acad Sci 2016; 1370:109-18
  6. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: Implications for cellbased therapies. Tissue Eng 2001;7(2):211-28
  7. Kolaparthy LK, Sanivarapu S, Moogla S, Kutcham RS. Adipose tissue-adequate, accessible regenerative material. Int J Stem Cells 2015;8:121-7
  8. Bersenev A. Cell therapy clinical trials-2014 report. Cell Trials Blog, 2015
  9. Fellows CR, Matta C, Zakany R, Khan İM, Mobasheri A. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. Front Genet 2016;7:213
  10. Tatullo M, Codispoti B, Pacifici A, Palmieri F, Marrelli M, Pacifici L, Paduano F. Potential use of human periapical cyst-mesenchymal stem cells (hPCy-MSCs) as a novel stem cell source for regenerative medicine applications. Front Cell Dev Biol 2017;5:103
  11. Mobasheri A, Kalamegam G, Musumeci G, Batt ME. Maturitas chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions 2014; 78(3):188-98
  12. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatology 2010; 6(11):625-35
  13. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000;97(25):13625 30
  14. Alsalameh S, Amin R, Gemba T, Lotz M. Identification of mesenchymal progenitor cells in normal and osteoarthrit